Literature DB >> 11751481

Vascularity and uptake of photosensitizer in small human tumor nodules: implications for intraperitoneal photodynamic therapy.

C Menon1, S N Kutney, S C Lehr, S K Hendren, T M Busch, S M Hahn, D L Fraker.   

Abstract

PURPOSE: i.p. spread of cancers is a common clinical problem, with limited treatment options leading to morbidity and death. i.p. photodynamic therapy (IP-PDT) combines maximal surgical debulking of gross tumor with intraoperative light delivery to the peritoneum after preoperative i.v. injection of photosensitizer to treat residual disease. An issue of concern in IP-PDT is the potential lack of photosensitizer uptake by residual small tumor nodules (STNs) < or =5 mm in maximum diameter and by microscopic residual disease caused by incomplete development of a vascular supply. This study examined the existence of vasculature and Photofrin (PF) uptake in STNs in 12 patients in a Phase II clinical trial for IP-PDT. EXPERIMENTAL
DESIGN: Patients received PF 2.5 mg/kg i.v. 48 h before surgery. STNs obtained during surgery were cryosectioned, immunostained for platelet/endothelial cell adhesion molecule 1, and analyzed by light microscopy. Mean vascular densities in STNs were determined by counting microvessels within a x200 field (0.28 mm(2) area). Sections were also examined for PF uptake by fluorescence image analysis using an epifluorescence microscope and IPLab Spectrum software.
RESULTS: Data obtained showed that tumors as small as 1 mm in diameter stained positive for platelet/endothelial cell adhesion molecule 1 and contained PF. A negative control from a patient not given PF showed no detectable fluorescence. The average of all mean vascular densities in STNs was determined to be 100 +/- 29.
CONCLUSIONS: We conclude that STNs, as small as 1 mm in diameter, have a functional vasculature, because these tumors show PF uptake after i.v. delivery. Both properties are crucial for the treatment of residual STNs by IP-PDT after surgical debulking.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11751481

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  4 in total

1.  Lymph node metastasis detection of ovarian cancer by porphyrin fluorescence photodetection: case report.

Authors:  Peter Hillemanns; Jessica Reiff; Herbert Stepp; Philipp Soergel
Journal:  Lasers Med Sci       Date:  2007-01-09       Impact factor: 3.161

2.  Synergistic enhancement of carboplatin efficacy with photodynamic therapy in a three-dimensional model for micrometastatic ovarian cancer.

Authors:  Imran Rizvi; Jonathan P Celli; Conor L Evans; Adnan O Abu-Yousif; Alona Muzikansky; Brian W Pogue; Dianne Finkelstein; Tayyaba Hasan
Journal:  Cancer Res       Date:  2010-11-09       Impact factor: 12.701

3.  PDT dose parameters impact tumoricidal durability and cell death pathways in a 3D ovarian cancer model.

Authors:  Imran Rizvi; Sriram Anbil; Nermina Alagic; Jonathan Celli; Jonathan P Celli; Lei Zak Zheng; Akilan Palanisami; Michael D Glidden; Brian W Pogue; Tayyaba Hasan
Journal:  Photochem Photobiol       Date:  2013-04-04       Impact factor: 3.421

4.  Photodynamic therapy with 3-(1'-hexyloxyethyl) pyropheophorbide a for cancer of the oral cavity.

Authors:  Nestor Rigual; Gal Shafirstein; Michele T Cooper; Heinz Baumann; David A Bellnier; Ulas Sunar; Erin C Tracy; Daniel J Rohrbach; Gregory Wilding; Wei Tan; Maureen Sullivan; Mihai Merzianu; Barbara W Henderson
Journal:  Clin Cancer Res       Date:  2013-10-02       Impact factor: 12.531

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.